Genome-wide off-target analyses of CRISPR/Cas9-mediated T-cell receptor engineering in primary human T cells. Kaeuferle T, Stief TA, Canzar S, Kutlu N, Willier S, Stenger D, Ferrada-Ernst P, Habjan N, Peters A, Busch DH, Feuchtinger T. (2022). Clin. Transl. Immunol. 11:e1372.
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins. Blaeschke F, Stenger D, Apfelbeck A, Cadilha BL, Benmebarek MR, Mahdawi J, Ortner E, Lepenies M, Habjan N, Rataj F, Willier S, Kaeuferle T, Majzner RG, Busch DH, Kobold S, Feuchtinger T. (2021). Blood Cancer J. 11(6):108.
Protective T-cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Stief TA, Kaeuferle T, Müller TR, Döring M, Jablonowski LM, Schober K, Feucht J, Dennehy KM, Willier S, Blaeschke F, Handgretinger R, Lang P, Busch DH, Feuchtinger T. (2021). Mol Ther. S1525-0016(21)00303-8.
CLEC12A and CD33 co-expression as preferential target on pediatric AML for combinatorial immunotherapy. Willier S, Rothämel P, Hastreiter M, Wilhelm J, Stenger J, Blaeschle F, Rohlfs M, Kaeuferle T, Schmid I, Albert M H, Binder V, Subklewe M, Klein C, Feuchtinger T. (2021). Blood 137(8):1037-1049.
Leukemia escape in immune desert: intraocular relapse of pediatric pro-B-ALL during systemic control by CD19-CAR T cells. Willier S, Raedler J, Blaeschke F, Stenger D, Pazos Escudero M, Jurgeleit F, Grünewald T G P, Binder V, Schmid I, Albert M H, Wolf A, Feuchtinger T. (2020). J Immunother Cancer. 8(2):e001052.
Leukemia-induced dysfunctional
TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric
B-precursor ALL patients. Blaeschke F, Willier S, Stenger D, Lepenies M,
Horstmann MA, Escherich G, Zimmermann M, Rojas Ringeling F, Canzar S, Kaeuferle
T, Rohlfs M, Binder V, Klein C, Feuchtinger T. (2020). Leukemia 34(10):
2607-2620.
Endogenous TCR promotes in vivo
persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout
CAR. Stenger D, Stief T A, Kaeuferle T, Willier S, Rataj F, Schober K, Vick B,
Lotfi R, Wagner B, Grünwald T G P, Kobold S, Busch D H, Jeremias I, Blaeschke
F, Feuchtinger T. (2020). Blood 136(12):1470-1418.
CRISPR-Cas9-Mediated
Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy
Posttransplantation. Kaeuferle T, Deisenberger L, Jablonowski L, Stief
TA, Blaeschke F, Willier S, Feuchtinger T. (2020). Mol Ther. 28(9):1965-1973.
Strategies of adoptive T -cell transfer
to treat refractory viral infections post allogeneic stem cell transplantation. Kaeuferle T, Krauss R, Blaeschke F, Willier S,
Feuchtinger T. (2019). J
Hematol Oncol. 6;12(1):13.
Efficacy, safety and feasibility
of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting
in pediatric patients receiving moderately and highly emetogenic chemotherapy -
results of a non-interventional observation study. Willier S, Cabanillas
Stanchi KM, von Have M, Binder V, Blaeschke F, Feucht J, Feuchtinger T, Döring
M. (2019). BMC Cancer. 15(1): 1118.
Low mutational load in pediatric
medulloblastoma still translates into neoantigens as targets for specific
T-cell immunotherapy. Blaeschke F, Paul MC, Schuhmann MU, Rabsteyn A,
Schroeder C, Casadei N, Matthes J, Mohr C, Lotfi R, Wagner B, Kaeuferle T,
Feucht J, Willier S, Handgretinger R, StevanoviĆ S, Lang P, Feuchtinger T.
(2019). Cytotherapy. 21(9):973-986.
Induction of a central memory and
stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells
produced in an automated good manufacturing practice system for the treatment
of CD19+ acute lymphoblastic leukemia. Blaeschke
F, Stenger D, Kaeuferle T, Willier S, Lotfi R, Kaiser AD, Assenmacher M, Döring
M, Feucht J, Feuchtinger T. (2018).
Cancer Immunol Immunother 67(7):1053-1066.
T-cell responses against CD19+ pediatric acute
lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are
regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Feucht J,
Kayser S, Gorodezki D, Hamieh M, Döring M, Blaeschke F, Schlegel P, Bösmüller
H, Quintanilla-Fend L, Ebinger M, Lang P, Handgretinger R, Feuchtinger T. (2016) Oncotarget 22;7(47):76902-76919.
Adoptive T-cell therapy with hexon-specific Th1 cells
as a treatment of refractory adenovirus infection after HSCT. Feucht J, Opherk K, Lang P, Kayser S, Hartl L,
Bethge W, Matthes-Martin S, Bader P, Albert MH, Maecker-Kolhoff B, Greil J,
Einsele H, Schlegel PG, Schuster FR, Kremens B, Rossig C, Gruhn B, Handgretinger
R, Feuchtinger T. (2015) Blood
19;125(12):1986-94.
Adoptive transfer of epstein-barr virus (EBV) nuclear
antigen 1-specific t cells as treatment for EBV reactivation and
lymphoproliferative disorders after allogeneic stem-cell transplantation. Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos
C, Bethge W, Greil J, Albert MH, Schwinger W, Nathrath M, Schumm M, Stevanovic
S, Handgretinger R, Lang P, Feuchtinger T. (2013)
J Clin Oncol. 31(1):39-4.
Further publications: Pubmed
